Treatment of autoimmune hemorrhagic disease Sassy Ness Innovative Therapy approved to expand scope of application

Immunoglotoglobulism is a rare autoimmune hemorrhagic disease that affects about 60,000 adults in the United StatesThe patient's symptoms are a small number of platelets, leading to excessive bruising and severe bleedingITP is considered chronic when symptoms persist for more than 12 monthsThe state of fatigue and depression is often associated with ITP, and daily fears of severe bleeding limit the patient's working life and social and leisure activitiesalthough there is no cure, platelet-producing receptor agonists (TPO-RA) are often used to effectively manage diseaseHowever, factors such as weekly subcutaneous administration, potential liver toxicity and food restrictions may be important barriers to effective treatment of TPO-RADoptelet (avatrombopag) is an oral TPO-RA taken with food that simulates the effects of TPO, the main regulator for normal platelet productionDoptelet was approved by the FDA in May last year to treat thrombocytopenia in adult patients who will undergo surgery for chronic liver disease (CLD)Doptelet (Photo: Doptelet.com)In key Phase 3 clinical studies, Doptelet administration resulted in a platelet count of at least 50,000 / sl in most patients on the eighth day of treatment, and during a six-month course of treatment, Doptelet maintained platelet counts that performed better than placebo within the target rangeOther efficacy data supporting the application come from two Phase 2 clinical trials treating ITP and two Phase 3 clinical trials treating platelet reduction in CLD patients"DOVE is pleased to provide patients and doctors with Doptelet for the treatment of chronic ITP adult patients who have underresponded previous therapies," said DrDavid Zaccardelli, President and CEO of DOVE"In addition to providing new treatment options for ITP patients, we expect Doptelet to address critical unmet medical needs." We sincerely thank the patients and dedicated researchers involved in our clinical programReferences:Retrieved June 27, 2019, from http://investors.dova.com/news-releases/news-release-details/dova-pharmaceuticals-announces-fda-approval-supplemental-new